Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 8/20 | 0.44 |
| ▸ | CDK4 | P11802 | 7/20 | 0.44 |
| ▸ | CCND1 | P24385 | 6/20 | 0.44 |
| ▸ | CCND2 | P30279 | 6/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.42 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | NEK2 | P51955 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035280 | 0.85 | TNK2 (0.52) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15041299 | 0.79 | CDK4 (0.64) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035278 | 0.78 | CDK4 (0.50) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035272 | 0.74 | FGFR1 (0.57) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035264 | 0.74 | CDK4 (0.51) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035284 | 0.73 | CDK4 (0.51) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035271 | 0.73 | CDK4 (0.50) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL16510429 | 0.72 | PAK1 (0.62) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL15035270 | 0.72 | PAK1 (0.54) | TNK2CCND3CDK4CCND1CCND2 | |
| SCHEMBL10192607 | 0.70 | ALK (0.49) | CDK4CCND1ALKCDK2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885CCND3 2451/4885CDK4 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.